Samsung Biologics Amplifies Partnership with Bristol Myers Squibb, Scaling Up Production of Cutting-Edge Antibody Cancer Treatment

INCHEON, South Korea – Sept. 17, 2023 – Today, in a groundbreaking move, Samsung Biologics (KRX: 207940.KS) has unveiled a strategic alliance that promises to redefine the landscape of cancer treatment. Teaming up with the renowned Bristol Myers Squibb (NYSE: BMY), they’re embarking on a bold mission to revolutionize the production of a vital antibody cancer drug substance.

This collaboration marks the evolution of a long-standing partnership between Bristol Myers Squibb and Samsung Biologics, one that has grown stronger over the years. Under the terms of this new agreement, Samsung Biologics is set to take center stage at their state-of-the-art biomanufacturing facility, Plant 4, nestled in the vibrant heart of Songdo, South Korea. Here, they will undertake the monumental task of manufacturing the essential drug substance for a groundbreaking antibody cancer treatment.

John Rim, the visionary President and CEO of Samsung Biologics, expressed his enthusiasm, saying, “Our journey with Bristol Myers Squibb has spanned over a decade, and today, we stand proud and exhilarated to be at the forefront of delivering life-changing medicines to patients across the globe. This profound collaboration underscores our unwavering commitment to accelerating the delivery and ensuring a constant supply of therapies that lie within our clients’ pipelines. It’s a testament to our dedication to manufacturing excellence, innovation, and unmatched capacity.”

About Samsung Biologics Co., Ltd.

In the heart of innovation beats Samsung Biologics (KRX: 207940.KS), a true pioneer in the world of biopharmaceuticals. Picture this: a powerhouse, a one-stop wonder known for delivering a seamless journey in drug development and manufacturing. From the inception of cell lines to the final masterpiece of aseptic fill/finish, they are your guiding light.

Their facilities are A testament to cutting-edge brilliance, meticulously crafted to dance in harmony with the stringent cGMP standards. Imagine bioreactors spanning a spectrum of sizes, from small and intimate to grand and powerful, catering to every whim and fancy of their esteemed clientele.

Now, let’s talk numbers and ambition. Behold, the colossal Plant 4, standing tall as a symbol of triumph and growth. It’s a marvel, a behemoth boasting a total capacity of a whopping 604KL, showcasing Samsung Biologics’ might on a single grand canvas. But that’s not all. Brace yourself for the future as they unveil plans for Plant 5, a vision set to come alive in April 2025, promising even greater feats.

And across the ocean, Samsung Biologics America stands as a beacon of collaboration. It’s where dreams and ideas converge, especially for those on the American and European shores. A testament to their commitment to global excellence.

But here’s the real magic: they’re not just about the present; they’re visionaries of tomorrow. Imagine specialized facilities for the groundbreaking antibody-drug conjugates (ADCs) and a dedicated haven for mRNA manufacturing. Picture extra aseptic filling capacity ready to fuel the future of medicine.

This is more than a partnership; this is a promise. A promise of timeliness, of perfection, of adaptability. Their tale is one of proven expertise and operational brilliance. When you choose Samsung Biologics, you’re choosing a future where possibilities are limitless.

Leave a Comment